At a Glance
- Company: Ambrosia Biosciences Inc.
- Location: Boulder, Colorado, US
- Deal value: $100M oversubscribed Series B (total raised ~$125M+)
- Focus area: AMB-234, oral small-molecule GLP-1R agonist for obesity and cardiometabolic disorders
- Next steps: IND-enabling studies, Phase 1 initiation; advance GIPR and amylin pipeline
What happened?
Ambrosia Biosciences closed an oversubscribed $100 million Series B on 31 March 2026, co-led by Blue Owl Healthcare Opportunities, Redmile Group and Deep Track Capital, with participation from existing investors BVF Partners and Boulder Ventures plus new backers Janus Henderson Investors and Samsara BioCapital. Proceeds will fund IND-enabling studies and Phase 1 clinical trials for lead oral GLP-1 receptor agonist AMB-234, alongside discovery work on its GIPR antagonist and amylin agonist programmes.
Why does it matter?
The round arrives as the oral GLP-1 market accelerates rapidly: Novo Nordisk’s oral Wegovy was approved in December 2025, Eli Lilly’s orforglipron holds a PDUFA date in April 2026, and Structure Therapeutics reported 16% average weight loss for its oral candidate ahead of Phase 3. Ambrosia’s cryo-EM and AI-driven platform targets 24-hour receptor coverage and combination potential, differentiating it from peptide-based oral approaches by offering potentially lower doses, no food or water restrictions, and greater combinability with complementary metabolic targets.
Who’s behind it?
Founded by CEO Nick Traggis on the former Array BioPharma campus in Boulder, Ambrosia built its approach around cryo-EM structural biology and AI-powered molecular design for Class B G-protein coupled receptors including GLP-1R, GIPR and the amylin receptor. Prior investors include Merck, which led the company’s $25 million Series A, providing early pharma validation for the platform and positioning Ambrosia as a credible competitor to Septerna and Structure Therapeutics in the small-molecule GPCR obesity space.
How was it achieved?
AMB-234 was presented at ObesityWeek 2025 and recognised with a Colorado BioScience Rising Star Award, with preclinical data demonstrating a novel, orally bioavailable GLP-1R agonist profile suitable for once-daily dosing. The oversubscribed nature of the round reflects conviction in both the asset and the broader anti-obesity drug market, now valued at $22.5 billion in 2026 and projected to reach $196 billion by 2036.
What’s next?
Ambrosia will use the capital to progress AMB-234 through IND-enabling toxicology and safety studies before initiating a Phase 1 trial in obesity or metabolic disease, potentially generating first-in-human data in 2027. In parallel, the company will advance GIPR antagonist and amylin agonist discovery programmes, laying the groundwork for next-generation combination therapies targeting multiple metabolic pathways simultaneously.
What are people saying?
CSO John Mayer: “AMB-234 represents a novel, orally bioavailable approach to GLP-1R agonism with 24-hour coverage potential.” Investors: “Growth-stage conviction in Ambrosia’s platform,” noting co-lead Blue Owl is part of a $300B+ AUM firm with strong healthcare-sector conviction.